Molecular biomarkers in cardiac hypertrophy

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Biomarker Discovery

Background:

• Cardiac hypertrophy, an increase in myocyte size without cell division, is an adaptive response to cardiac wall stress and enhanced afterload.
• Myocardial remodeling due to cardiac hypertrophy is linked to heart dysfunction, a major cause of morbidity and mortality in the elderly.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying the development and progression of myocardial hypertrophy.
• To identify key molecules, including micro-RNAs and specific biomarkers, involved in cardiac hypertrophy pathogenesis.

Main Methods:

• Review and synthesis of existing scientific literature on molecular involvement in cardiac hypertrophy.
• Identification of critical molecular players, such as micro-RNAs and specific protein biomarkers.

Main Results:

• Micro-RNAs are increasingly recognized for their role in the pathogenesis of cardiac hypertrophy.
• Key molecular biomarkers, including vascular endothelial growth factor B, NAD-dependent deacetylase sirtuin-3, growth/differentiation factor 15, and glycoprotein 130, are implicated in myocardial hypertrophy development.

Conclusions:

• Understanding the regulatory mechanisms of these identified biomarkers in the heart is crucial.
• This knowledge may facilitate the discovery of novel molecular targets for effective treatment of cardiac hypertrophy.